On Friday morning, President Trump received an experimental treatment for Covid-19 developed by Regeneron. At the time, it had only been provided to fewer than 10 patients outside of clinical trials, under so-called compassionate use. Data for the drug had been presented for the first time earlier that week on a company conference call.
It was, to put it mildly, an unusual situation.
“Obviously your heart races a little bit faster when you’re dealing with a leader of the free world and you realize you might be in a position to really change the course of his health outcome,” said Leonard Schleifer, Regeneron’s founder and CEO told STAT. “So, it’s certainly … I’m trying to find the right adjective. It’s intense, for sure.”
About the Author Reprints
